Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Terminated Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

NCT06425159
View directory record Official record
Conditions
Generalized Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

NCT01002742
View directory record Official record
Conditions
Graft-versus-Host Disease, Immune System Disorders
Interventions
Mycophenolate Mofetil, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Duarte, California • La Jolla, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 14, 2026, 10:19 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis

NCT07776405
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
transdermal CBD cream (Tolcylen®, Marlinz Pharma), Matched Placebos
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

NCT03859973
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Encino, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 14, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

NCT00597428
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
109
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tempe, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

NCT03918629
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
1,994 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
52
States / cities
Athens, Alabama • Huntsville, Alabama • Chandler, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

NCT03235219
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ-64565111, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moringa Supplementation for Improved Milk Output

NCT05333939
View directory record Official record
Conditions
Breastfeeding
Interventions
Moringa leaf powder, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kentucky
Other
Eligibility
0 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 14, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Results available

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

NCT04423757
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 14, 2026, 10:19 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

NCT03464136
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
Biological
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 14, 2026, 10:19 PM EDT
Recruiting Not applicable Interventional

Impact of Biophoton Therapy on Chronic Severe Arthritis Pain

NCT06915012
View directory record Official record
Conditions
Arthritis
Interventions
Tesla BioHealing(R) Biophoton Generators
Device
Lead sponsor
First Institute of All Medicines
Other
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Not applicable Interventional Results available

Mechanisms of Antidepressant Non-Response in Late-Life Depression

NCT01931202
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo oral tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Results available

Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.

NCT00320281
View directory record Official record
Conditions
Spinal Cord Injury, Pain
Interventions
botulinum toxin A, placebo
Drug · Other
Lead sponsor
Craig Hospital
Other
Eligibility
15 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Medication-based Analgesia in Humans

NCT02901275
View directory record Official record
Conditions
Pain, Cannabis, Opioid Use, Unspecified
Interventions
Within-subject test of blinded study medications
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 14, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Plantar Fasciitis With Xeomin

NCT01678001
View directory record Official record
Conditions
Plantar Fascitis
Interventions
Xeomin
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 14, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
LB-102, Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
Drug · Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Results available

Adjunctive Isradipine for the Treatment of Bipolar Depression

NCT01784666
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Isradipine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 14, 2026, 10:19 PM EDT
Terminated Phase 3 Interventional Results available

Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation

NCT02177266
View directory record Official record
Conditions
Atrial Fibrillation, Post-pericardiotomy Syndrome, Constriction
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 14, 2026, 10:19 PM EDT